Investigating proteins that may reduce lung scarring in pulmonary fibrosis
Microfibril-associated glycoproteins attenuating pulmonary fibrosis
This study is looking at how certain proteins made by cells in the lungs might help us find new ways to treat idiopathic pulmonary fibrosis (IPF), a tough lung disease, by understanding their role in lung scarring and damage.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11201100 on NIH RePORTER |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by progressive scarring and limited treatment options. The study examines the role of microfibril-associated glycoproteins (Magp1 and Magp2) produced by fibroblasts, which may help regulate a key signaling pathway involved in fibrosis. By understanding how these proteins interact with transforming growth factor beta (TGFB), the research aims to identify new therapeutic strategies that could mitigate lung damage and improve patient outcomes. The approach includes genetic studies in mice to explore the effects of these proteins on lung injury and fibrosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing progressive lung symptoms.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce lung scarring and improve breathing in patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in fibrosis, indicating potential for success in this novel approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Koenitzer, Jeffrey — Washington University
- Study coordinator: Koenitzer, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.